{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:39:56Z","timestamp":1756190396879,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This retrospective study evaluated 66 patients diagnosed with relapsed and\/or refractory mantle cell lymphoma (R\/R MCL) treated with ibrutinib in Spain in routine clinical practice. At diagnosis, patients had a median age of 64.5\u00a0years, 63.6% presented with intermediate\/high sMIPI (simplified prognostic index for advanced-stage mantle cell lymphoma), 24.5% had the blastoid variant, and 55.6% had a Ki67\u2009&gt;\u200930%. Patients had received a median of 2 prior lines of therapy (range 1\u20132; min\u2013max 1\u20137). Overall response rate was 63.5%, with 38.1% of patients achieving complete response (CR). With a median duration of ibrutinib exposure of 10.7\u00a0months (range 5.2\u201319.6; min\u2013max 0.3\u201336), the median progression-free survival (PFS) and overall survival (OS) were 20\u00a0months [95% confidence interval (CI) 8.8\u201331.1] and 32\u00a0months (95% CI 22.6\u201341.3), respectively, and were not reached in patients achieving CR. No grade\u2009\u2265\u20093 cardiovascular toxicity or bleeding was reported. This study supports that treatment with ibrutinib leads to high response rates and favorable survival outcomes in patients with R\/R MCL.<\/jats:p>","DOI":"10.1007\/s12185-022-03367-z","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T11:08:00Z","timestamp":1652440080000},"page":"381-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["IBRORS-MCL study: a Spanish retrospective and observational study of relapsed\/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan-Manuel","family":"Sancho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mar\u00edn-Niebla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco-Javier","family":"Capote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Ca\u00f1igral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izaskun","family":"Zeberio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose-Manuel","family":"Puerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"P\u00e9rez-Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Vale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mart\u00edn Garc\u00eda-Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gonz\u00e1lez-Barca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anabel","family":"Teruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Pastoriza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Conde-Royo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"S\u00e1nchez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Barrenetxea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyes","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-\u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Jos\u00e9","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aroa","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Rubio-Azpeitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"19","key":"3367_CR1","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724\u201334.","journal-title":"Blood"},{"issue":"1","key":"3367_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","volume":"182","author":"P McKay","year":"2018","unstructured":"McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182(1):46\u201362.","journal-title":"Br J Haematol"},{"issue":"4","key":"3367_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","volume":"27","author":"A Herrmann","year":"2009","unstructured":"Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3367_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al. 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410\u20138.","journal-title":"Br J Haematol"},{"issue":"10044","key":"3367_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565\u201375.","journal-title":"Lancet"},{"issue":"6","key":"3367_CR6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/bjh.15723","volume":"184","author":"S Rule","year":"2019","unstructured":"Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2019;184(6):999\u20131005.","journal-title":"Br J Haematol"},{"issue":"6","key":"3367_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"key":"3367_CR8","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1182\/blood.V124.21.4471.4471","volume":"124","author":"M Wang","year":"2014","unstructured":"Wang M, Goy A, Martin P, Ramchandren R, Alexeeva J, Popat R, et al. Efficacy and safety of single-agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. Blood. 2014;124:4471.","journal-title":"Blood"},{"issue":"10020","key":"3367_CR9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770\u20138.","journal-title":"Lancet"},{"issue":"5","key":"3367_CR10","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","volume":"104","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211\u20134.","journal-title":"Haematologica"},{"issue":"34","key":"3367_CR11","doi-asserted-by":"publisher","first-page":"23443","DOI":"10.18632\/oncotarget.25215","volume":"9","author":"A Broccoli","year":"2018","unstructured":"Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, et al. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed\/refractory mantle cell lymphoma. Oncotarget. 2018;9(34):23443\u201350.","journal-title":"Oncotarget"},{"issue":"4","key":"3367_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hon.2380","volume":"35","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study. Hematol Oncol. 2017;35(4):528\u201335.","journal-title":"Hematol Oncol"},{"issue":"16","key":"3367_CR13","doi-asserted-by":"publisher","first-page":"6860","DOI":"10.1002\/cam4.2565","volume":"8","author":"YW Jeon","year":"2019","unstructured":"Jeon YW, Yoon S, Min GJ, Park SS, Park S, Yoon JH, et al. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Med. 2019;8(16):6860\u201370.","journal-title":"Cancer Med"},{"issue":"2","key":"3367_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/bjh.17363","volume":"193","author":"R McCulloch","year":"2021","unstructured":"McCulloch R, Lewis D, Crosbie N, Eyre TA, Bolam S, Arasaretnam A, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol. 2021;193(2):290\u20138.","journal-title":"Br J Haematol"},{"issue":"6","key":"3367_CR15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/bjh.16739","volume":"192","author":"D Tucker","year":"2021","unstructured":"Tucker D, Morley N, MacLean P, Vandenberghe E, Booth S, Parisi L, et al. The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed\/refractory mantle cell lymphoma. Br J Haematol. 2021;192(6):1035\u20138.","journal-title":"Br J Haematol"},{"issue":"3","key":"3367_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/cac2.12150","volume":"41","author":"JH Yi","year":"2021","unstructured":"Yi JH, Kim SJ, Yoon DH, Suh C, Chang MH, Yang DH, et al. Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. Cancer Commun (Lond). 2021;41(3):275\u20138.","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"3367_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/bjh.14870","volume":"179","author":"S Rule","year":"2017","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"3367_CR18","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood-2019-124691","volume":"134","author":"S Rule","year":"2019","unstructured":"Rule S, Dreyling M, Goy A, Hess G, Auer R, Kahl B, et al. Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. Blood. 2019;134(1):1538.","journal-title":"Blood"},{"issue":"2","key":"3367_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","volume":"125","author":"K Maddocks","year":"2015","unstructured":"Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, et al. A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma. Blood. 2015;125(2):242\u20138.","journal-title":"Blood"},{"issue":"4","key":"3367_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bjh.16416","volume":"189","author":"R McCulloch","year":"2020","unstructured":"McCulloch R, Visco C, Eyre TA, Frewin R, Phillips N, Tucker DL, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684\u20138.","journal-title":"Br J Haematol"},{"issue":"4","key":"3367_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578\u201387.","journal-title":"Br J Haematol"},{"issue":"1","key":"3367_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000510","volume":"5","author":"CW Eskelund","year":"2021","unstructured":"Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, Raty R, Gjerdrum LMR, et al. Detailed long-term follow-up of patients who relapsed after the Nordic mantle cell lymphoma trials: MCL2 and MCL3. Hemasphere. 2021;5(1): e510.","journal-title":"Hemasphere"},{"issue":"6","key":"3367_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175\u20139.","journal-title":"Ann Oncol"},{"issue":"12","key":"3367_CR24","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Post ibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559\u201363.","journal-title":"Blood"},{"issue":"1","key":"3367_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","volume":"10","author":"M Wang","year":"2017","unstructured":"Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3367_CR26","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68\u201371.","journal-title":"Haematologica"},{"issue":"1","key":"3367_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","volume":"54","author":"P Dreger","year":"2019","unstructured":"Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT chronic malignancies and lymphoma working parties. Bone Marrow Transplant. 2019;54(1):44\u201352.","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"3367_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"3367_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2019-127508","volume":"134","author":"JS Abramson","year":"2019","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas. Blood. 2019;134(1):241.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03367-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03367-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03367-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T16:09:51Z","timestamp":1661011791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03367-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3367"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03367-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JM Sancho: speaker fees for educational events from Roche, Janssen, Gilead-Kite, BMS-Celgene, Novartis, Takeda and Servier; Advisory boards for Roche, Janssen, Gilead-Kite, BMS-Celgene, Novartis, Incyte, Beigene and Lilly. A Mar\u00edn Niebla: honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen, Takeda, Kiowa Kirin, Gilead, Lilly, Abbvie; Support for attending meetings and\/or travel from Janssen, Takeda, Kiowa Kirin. FJ Capote: honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen, Takeda, Roche, BMS, Celgene, Amgen; Support for attending meetings and\/or travel from Janssen, Takeda, Roche, BMS, Celgene, Amgen; advisory board for Janssen, Takeda, Roche, BMS, Celgene, Amgen; C Grande: advisory boards, symposia and attending conferences from Janssen. I Zeberio: honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Gilead, Novartis, Roche; Support for attending meetings and\/or travel from BMS, Gilead, Janssen, Novartis, Roche, Incyte; advisory boards for BMS, Gilead, Janssen, Novartis, Roche, Incyte. JM Puerta: support for attending meetings from Novartis, Roche, Abbvie, Janssen, Astrazeneca, Gilead; Advisory boards for Roche, Novartis, Janssen, BMS; Financial support for research from Novartis, Roche, Pfizer. A Rivas: support for attending meetings and travel from Janssen, Kite and Takeda. E P\u00e9rez Ceballos: advisory boards for Takeda, Janssen, Incyte; honoraria for presentations from Takeda and Roche. A Vale: honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Janssen, Astrazeneca. A Mart\u00edn Garc\u00eda-Sancho: consulting fees from Roche, Celgene\/BMS, Morphosys, Kyowa Kirin, Clinigen, Eusa Pharma, Novartis, Gilead, Servier, Incyte; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Celgene\/BMS, Janssen, Servier, Gilead, Takeda, EUSAPharma; Payment for expert testimony from Gilead, Roche; Support for attending meetings and\/or travel from Roche, Servier, Celgene, Janssen, Kern Pharma. A Salar: Grants or contracts from Gilead; Consulting fees from Incyte and Beigene; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, EUSA Pharma, Janssen, BMS\/Celgene. E Gonz\u00e1lez Barca: Consultancy from Janssen, Abbvie, Gilead, Kiowa, EUSA Pharma, Incyte, Lilly, Beigene, Novartis; Speaker fees: Janssen, Abbvie, Takeda, Roche, EUSA Pharma, Incyte; Travel grants: Janssen, Abbvie, Roche, EUSA Pharma. C. Pastoriza: support for attending meetings and\/or travel from Janssen, Amgen and Abbvie. D. Conde-Royo: speaker fees from Janssen, Abbvie, Takeda. J S\u00e1nchez-Garc\u00eda: honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Janssen, Abbvie, Pfizer. C Barrenetxea: honoraria for lecture fees from Janssen, Alexion and Takeda, and educational events from GSK. R Arranz: advisory Boards for Takeda and EUSA Pharma. JA Hern\u00e1ndez-Rivas: grants or contracts from BMS-Celgene, Sanofi; Honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen, Roche, Abbvie, AstraZeneca, Lilly, Gilead, BMS-Celgene, Amgen, Takeda; advisory board for Janssen, Roche, Abbvie, AstraZeneca, Beigene, Lilly, Gilead, BMS-Celgene, Amgen, Takeda, Jazz Pharmaceuticals, Rovi. A Jim\u00e9nez and E Rubio-Azpeitia are employees of Janssen. S Fern\u00e1ndez, C Ca\u00f1igral, E Donato, A Teruel and MJ Ramirez have nothing to disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}